Morgan Stanley Remains a Hold on Dexcom (DXCM)

By Austin Angelo

Morgan Stanley analyst David Lewis maintained a Hold rating on Dexcom (DXCMResearch Report) today and set a price target of $278.00. The company’s shares closed last Monday at $262.63.

According to TipRanks.com, Lewis is a 4-star analyst with an average return of 3.0% and a 53.9% success rate. Lewis covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Zimmer Biomet Holdings, and Baxter International.

Currently, the analyst consensus on Dexcom is a Strong Buy with an average price target of $294.17.

See today’s analyst top recommended stocks >>

The company has a one-year high of $306.71 and a one-year low of $107.44. Currently, Dexcom has an average volume of 1.08M.

Based on the recent corporate insider activity of 134 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of DXCM in relation to earlier this year. Earlier this month, Steven Robert Pacelli, the EVP Strategy and Corporate Dev of DXCM bought 8,927 shares for a total of $87,485.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

DexCom, Inc. is a medical device manufacturing company. The firm engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G4 PLATINUM System, DexCom G5 Mobil, DexCom Share and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.